Zobrazeno 11 - 20
of 37
pro vyhledávání: '"Christina Falcon"'
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Purpose:Invasive mucinous adenocarcinoma (IMA) is a unique subtype of lung adenocarcinoma, characterized genomically by frequent KRAS mutations or specific gene fusions, most commonly involving NRG1. Comprehensive analysis of a large series of IMAs u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c578c511345745010ca79b4dd6702a1
https://doi.org/10.1158/1078-0432.c.6530487
https://doi.org/10.1158/1078-0432.c.6530487
Autor:
Alexander Drilon, Ahmet Zehir, Paul Paik, Natasha Rekhtman, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Bob T. Li, Ryma Benayed, Ronglai Shen, Deepu Alex, Todd Hembrough, Fabiola Cecchi, Yuan Tian, Kerry Scott, Christina Falcon, Alex Makhnin, Caroline G. McCarthy, Olivia Wilkins, Jeffrey Girshman, Lukas Delasos, Andrew Chow, Jason Chang, A. Rose Brannon, Michael Offin, Robin Guo
Supplementary Figures S1-S6, Table S1-S3, and eMethods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c98a01f999507585f572e63c4b27511
https://doi.org/10.1158/1078-0432.22478177.v1
https://doi.org/10.1158/1078-0432.22478177.v1
Autor:
Alexander Drilon, Ahmet Zehir, Paul Paik, Natasha Rekhtman, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Bob T. Li, Ryma Benayed, Ronglai Shen, Deepu Alex, Todd Hembrough, Fabiola Cecchi, Yuan Tian, Kerry Scott, Christina Falcon, Alex Makhnin, Caroline G. McCarthy, Olivia Wilkins, Jeffrey Girshman, Lukas Delasos, Andrew Chow, Jason Chang, A. Rose Brannon, Michael Offin, Robin Guo
Purpose:MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14–altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a29c8230760e2c9e1f14ea1b86800ba
https://doi.org/10.1158/1078-0432.c.6529874
https://doi.org/10.1158/1078-0432.c.6529874
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Tables 1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58ff3a06d75d2cd8b0230c0c56ffac14
https://doi.org/10.1158/1078-0432.22480617
https://doi.org/10.1158/1078-0432.22480617
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Figure 4. Comparison of overall and recurrence-free survival in CDKN2A-wild type and CDKN2A-mutant IMAs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ea21c91b13511248ef21ba3e7053189
https://doi.org/10.1158/1078-0432.22480626.v1
https://doi.org/10.1158/1078-0432.22480626.v1
Autor:
Natasha Rekhtman, Alexander Drilon, Marc Ladanyi, William D. Travis, Maria E. Arcila, Alison M. Schram, Bob T. Li, Laetitia Borsu, Khedoudja Nafa, Ryma Benayed, Joshua K. Sabari, Sarah Teed, Valerie W. Rusch, Prasad S. Adusumilli, Kyuichi Kadota, Patrice Desmeules, Joseph Montecalvo, Sharon Amir, Helen H. Won, Vasilisa A. Rudneva, Fanli Meng, Brian R. Houck-Loomis, David Brown, Christina Falcon, Michael Offin, Jason C. Chang
Supplemental Figure 2. Detailed graphical visualizations of the F11R-NRG2 fusion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65fec13b6ee1ac118e42f6f089da3151
https://doi.org/10.1158/1078-0432.22480632.v1
https://doi.org/10.1158/1078-0432.22480632.v1
Autor:
Michael Duruisseaux, Philippe Brun, Valérie Gounant, Alison M. Schram, Maria E. Arcila, Yonina R. Murciano-Goroff, Miguel Angel Molina, Masaoki Ito, Morihito Okada, Joshua K. Sabari, Denis Moro-Sibilot, Clarisse Dupont, Christina Falcon, Lucia Anna Muscarella, Alexa B. Schrock, Torsten Blum, Alexander Drilon, Marie Wislez, Robert C. Doebele, Haiquan Chen, Eva Brandén, Siraj M. Ali, Fanny Magne, Misako Nagasaka, D. Ross Camidge, Sai-Hong Ignatius Ou, Giulio Rossi, Jin-Yuan Shih, Viola W. Zhu, Jacques Cadranel, Soo-Ryum Yang, Maurice Pérol, Isabelle Monnet, Stephen V. Liu, Rafael Rosell, Ji Youn Han
Publikováno v:
Journal of Clinical Oncology. 39:2791-2802
PURPOSEAlthough NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion–positive lung c
Autor:
Harper Hubbeling, Noura Choudhury, Jessica Flynn, Zhigang Zhang, Christina Falcon, Valerie W. Rusch, Bernard J. Park, Etay Ziv, Narek Shaverdian, Daphna Y. Gelblum, Annemarie F. Shepherd, Charles B. Simone, Abraham J. Wu, Daniel R. Gomez, Alexander Drilon, Andreas Rimner
Publikováno v:
JCO Precision Oncology.
PURPOSE Local therapy prolongs progression-free survival in patients with oligometastatic non–small-cell lung cancers treated with chemotherapy. We previously reported that local therapy also prolongs survival and time to next therapy in patients o
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Jason C. Chang, Todd Hembrough, Robin Guo, M. Offin, Caroline G. McCarthy, Natasha Rekhtman, Kerry Scott, Ryma Benayed, Deepu Alex, Alex Makhnin, Ahmet Zehir, Mark G. Kris, Fabiola Cecchi, Alexander Drilon, Ronglai Shen, A. Rose Brannon, Paul K. Paik, Bob T. Li, Jeffrey Girshman, Charles M. Rudin, Yuan Tian, Christina Falcon, Lukas Delasos, Olivia Wilkins, Andrew Chow, Maria E. Arcila
Publikováno v:
Clin Cancer Res
Purpose: MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14–altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomi